甲状腺功能减退症甲状腺激素治疗相关的人口学、医疗可及性与饮食因素
基于美国全国患者索赔数据(2010-2020)和NHANES数据(1999-2016)的平行横断面研究,纳入原发性或亚临床甲状腺功能减退症患者。年均47711名成人接受至少1次新甲状腺激素处方,其中88.3%为左甲状腺素单药治疗、2.0%为碘塞罗宁治疗、9.4%为干燥甲状腺提取物治疗;干燥甲状腺提取物治疗比例从2010年5.4%升至2020年10.2%。初级保健和内分泌科医生密度高与左甲状腺素单药治疗使用增加相关(比值比2.51,P<.001;比值比2.71,P<.001),干燥甲状腺提取物治疗者膳食补充剂使用更多(4.7 vs 2.1,P<.001)。
要点
- 2010-2020年间年均47711名成人接受新甲状腺激素处方,88.3%为左甲状腺素单药、2.0%为碘塞罗宁、9.4%为干燥甲状腺提取物。
- 干燥甲状腺提取物治疗比例从2010年5.4%增至2020年10.2%,碘塞罗宁治疗保持稳定。
- 医生密度高与左甲状腺素单药使用增加相关;干燥甲状腺提取物治疗者膳食补充剂使用更多(4.7 vs 2.1,P<.001)。
核心结论
- 自2010年以来,甲状腺功能减退症含干燥甲状腺提取物的新甲状腺激素治疗比例翻倍,而碘塞罗宁治疗保持稳定。
- 干燥甲状腺提取物治疗与医生密度降低和膳食补充剂使用增加相关。
研究设计与样本
- 平行横断面研究,使用两个数据集:全国患者索赔数据集(2010-2020)和全国健康与营养调查研究数据集(1999-2016)。
- 纳入参与者诊断为原发性或亚临床甲状腺功能减退症。
主要发现
- 年均47711名成人接受至少1次新甲状腺激素处方,其中88.3%接受左甲状腺素单药治疗、2.0%接受碘塞罗宁治疗、9.4%接受干燥甲状腺提取物治疗。
- 接受干燥甲状腺提取物治疗的比例从2010年5.4%上升至2020年10.2%。
- 州间分析显示,初级保健和内分泌科医生密度高与左甲状腺素单药治疗使用增加相关(比值比2.51,P<.001;比值比2.71,P<.001)。
- 全国健康与营养调查研究数据集中,干燥甲状腺提取物治疗者(n=73)较左甲状腺素治疗者(n=146)膳食补充剂使用更多(4.7 vs 2.1,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Clinical guidelines have recommended a trial of liothyronine (LT3) with levothyroxine (LT4) in select patients with hypothyroidism. However, little is known about the real-world use of LT3 and desiccated thyroid extract (DTE) and the characteristics of patients treated with LT3 and DTE. OBJECTIVES: (1) Determine national trends of new LT4, LT3, and DTE prescriptions in the United States; (2) determine whether sociodemographic, healthcare access, and dietary factors are associated with different thyroid hormone (TH) therapies. METHODS: Parallel cross-sectional studies were conducted using 2 datasets: (1) a national patient claims dataset (2010-2020) and (2) the National Health and Nutrition Examination Study (NHANES) dataset (1999-2016). Included participants had a diagnosis of primary or subclinical hypothyroidism. Study outcomes included the impact of demographics and healthcare access on differences in the proportion of TH therapies consisting of LT4, LT3, and DTE (patient claims) and differences in dietary behaviors between DTE-treated participants and LT4-treated matched controls (NHANES). RESULTS: On an average annual basis, 47 711 adults received at least 1 new TH prescription, with 88.3% receiving LT4 monotherapy, 2.0% receiving LT3 therapy, and 9.4% receiving DTE therapy. The proportion receiving DTE therapy increased from 5.4% in 2010 to 10.2% in 2020. In the analysis between states, high primary care and endocrinology physician densities were associated with increased use of LT4 monotherapy (odds ratio 2.51, P < .001 and odds ratio 2.71, P < .001). DTE-treated NHANES participants (n = 73) consumed more dietary supplements compared to LT4-treated participants (n = 146) (4.7 vs 2.1, P < .001). CONCLUSIONS: The proportion of new TH therapies containing DTE for hypothyroidism doubled since 2010 while LT3 therapies remained stable. DTE treatment was associated with decreased physician density and increased dietary supplement use.
引用
- Ettleson MD, Ibarra S, Wan W, et al. Demographic, Healthcare Access, and Dietary Factors Associated With Thyroid Hormone Treatments for Hypothyroidism. J Clin Endocrinol Metab. 2023. PMID: 37327351. doi:10.1210/clinem/dgad331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。